Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
British Journal of Pharmacology · 2026-07 · 183 (14) · 3935-3949
DOI: 10.1111/bph.70050 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2025-05-23. Written by Trevor Sharp and 1 co-authors. Institution: University Department of Pharmacology, Oxford, UK. Major MEDLINE topics: Hallucinogens, Serotonin 5-HT2 Receptor Agonists, Receptor, Serotonin, 5-HT2A, Mental Disorders. Cited 12 times so far (Crossref); 115 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council MRC-DTP Industrial Studentship for Aurelija Ippolito, University of Oxford, Medical Research Council.
Abstract (original language)
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s. However, these drugs are now experiencing a renaissance in the field of psychiatry based on increasing evidence that they can produce long‐lasting improvements in health across a wide variety of mental illnesses, including major depression, addictions and anxiety disorders. These drugs interact with many different 5‐HT receptor subtypes but the powerful psychedelic experience, which (depending on set and setting) includes profound alterations in perception, mood and cognition, accompanied by vivid hallucinations, is now widely considered mediated by an agonist action at 5‐HT 2A receptors. However, the link between the psychedelic experience, 5‐HT 2A receptor agonism and therapeutic effects is currently uncertain. Indeed, recent research has revealed a new class of 5‐HT 2A receptor agonists which appear to retain the therapeutic potential of psychedelics drugs without inducing disorienting hallucinatory experiences. Biased signalling, partial agonism and non‐selectivity at the 5‐HT 2A receptor are amongst the possible explanations for the differential properties of these drugs, whereas increased neuroplasticity offers a likely account of their common therapeutic effects. This article explores the neuropsychopharmacological properties of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists in the context of their promise as novel drug treatments in psychiatry. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University Department of Pharmacology, Oxford, UK.
ORCID profiles: Trevor Sharp
Funding
- Medical Research Council MRC-DTP Industrial Studentship for Aurelija Ippolito
- University of Oxford
- Medical Research Council
Cite
APA
Sharp, T., & Ippolito, A. (2026). Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists. British Journal of Pharmacology, 183(14), 3935-3949. https://doi.org/10.1111/bph.70050
Vancouver
Sharp T, Ippolito A. Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists. British Journal of Pharmacology. 2026;183(14):3935-3949. doi:10.1111/bph.70050
BibTeX
@article{Sharp2026,
author = {Sharp, Trevor and Ippolito, Aurelija},
title = {Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {14},
pages = {3935--3949},
doi = {10.1111/bph.70050}
}
EUVIMED